Primary outcome
What NCT01512108 measured first
| Measure | Liraglutide 0.9 mg/Dayn=240 | Additional OADn=120 |
|---|---|---|
| All AEs | 361 | 331 |
| Mild AEs | 345 | 321 |
| Moderate AEs | 14 | 9 |
| Severe AEs | 2 | 2 |
| Serious AEs | 5 | 9 |
Phase 3 · Liraglutide
NCT01512108 trial results
A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy
- Participants
- 363
- Status
- completed
- Completed
- 2013-04-26
- Sponsor
- Novo Nordisk A/S
As posted on ClinicalTrials.gov (NCT01512108), updated at source Dec 18, 2017. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
Side effects by arm
Side effects in NCT01512108
Percent of participants affected, Adverse events were captured from the time of consent until 52 weeks of treatment and if needed were followed up after the final visit.. The most common events the registry lists.
| Event | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Any serious event | 4.6% | 8.3% |
| Nasopharyngitis | 37.1% | 39.2% |
| Constipation | 18.3% | 10% |
| Diabetic retinopathy | 8.8% | 13.3% |
| Nausea | 12.9% | 3.3% |
| Diarrhoea | 8.3% | 7.5% |
| Abdominal discomfort | 7.9% | 0.8% |
| Cataract | 3.3% | 6.7% |
| Back pain | 5.4% | 2.5% |
| Dental caries | 2.9% | 5% |
| Influenza | 3.3% | 5% |
| Headache | 5% | 3.3% |
Secondary outcomes
What else it measured
| Liraglutide 0.9 mg/Dayn=240 | Additional OADn=120 |
|---|---|
| 7 | 2 |
| Liraglutide 0.9 mg/Dayn=239 | Additional OADn=120 |
|---|---|
| -1.21(0.05) | -0.94(0.07) |
| Liraglutide 0.9 mg/Dayn=239 | Additional OADn=120 |
|---|---|
| -1.55(0.09) | -1.24(0.12) |
The trial
How NCT01512108 was run
This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2 diabetes who are insufficiently controlled on OAD monotherapy. All subjects will continue their pre-trial OAD (either glinide, metformin, alpha-glucosidase inhibitor or thiazolidinedione) during the trial at unchanged type and dose.
- Liraglutide + an OAD therapy
- Two OADs combination therapy
Who could join the trial
Inclusion Criteria: * Informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject.) * Japanese subjects with type 2 diabetes on monotherapy with an OAD (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) within approved Japanese labelling in addition to diet and exercise therapy. Total daily dose and type of drug should have remained unchanged for at least 8 weeks prior to Visit 1 * Type 2 diabetes mellitus (clinically diagnosed) for at least 6 months * HbA1c between 7.0-10.0% (both inclusive) * Body Mass Index (BMI) below 40.0 kg/m\^2 * Outpatients who have no plans for an educational hospitalisation for the purpose of glycaemic control. However, hospitalisation for training of self-injection from Visit 2 that is for no longer than one week is allowed * Subjects able and willing to perform self-monitoring of plasma glucose (SMPG) Exclusion Criteria: * Subjects with known or previous malignant tumor and are strongly suspected of recurrence (except basal cell skin cancer or squamous cell skin cancer) * Calcitonin above or equal to 160 pg/mL * Personal history of non-familial medullary thyroid carcinoma * Family or personal history of multiple endocrine neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (FMTC) * History of chronic pancreatitis or idiopathic acute pancreatitis * Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months * Treatment with GLP-1 receptor agonist or dipeptidyl peptidase 4 (DPP-4) inhibitor within 12 weeks prior to Visit 1 * Having contraindications to liraglutide and any of the OADs (according to Japanese labelling)
Published papers
Papers from NCT01512108
- Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, Bosch-Traberg H, Seino Y. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016 Jan;7(1):76-84. doi: 10.1111/jdi.12367. Epub 2015 Jul 14.
- Kiyosue A, Seino Y, Nishijima K, Bosch-Traberg H, Kaku K. Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2018 Jul;9(4):831-839. doi: 10.1111/jdi.12759. Epub 2017 Nov 24.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.